Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 0.84 |
| ▸ | ITGAV | P06756 | 20/20 | 0.84 |
| ▸ | ITGB6 | P18564 | 16/20 | 0.84 |
| ▸ | ITGA2B | P08514 | 14/20 | 0.84 |
| ▸ | ITGB5 | P18084 | 11/20 | 0.84 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6219316 | 0.92 | ITGB3 (1.00) | ITGB3ITGAVITGB6ITGA2BITGB5 | |
| SCHEMBL6220938 | 0.90 | ITGB3 (0.69) | ITGB3ITGAVITGB6ITGA2BITGB5 | |
| SCHEMBL8348154 | 0.88 | ITGB3 (0.86) | ITGB3ITGAVITGB6ITGA2BITGB5 | |
| SCHEMBL6221711 | 0.88 | ITGB3 (0.86) | ITGB3ITGAVITGB6ITGA2BITGB5 | |
| SCHEMBL6220781 | 0.86 | ITGB3 (0.85) | ITGB3ITGAVITGB6ITGA2BITGB5 | |
| SCHEMBL6223622 | 0.83 | ITGB3 (0.86) | ITGB3ITGAVITGB6ITGA2BITGB5 | |
| SCHEMBL5848387 | 0.82 | ITGB3 (0.75) | ITGB3ITGAVITGB6ITGA2BITGB5 | |
| SCHEMBL6221090 | 0.82 | ITGB3 (0.81) | ITGB3ITGAVITGB6ITGA2BITGB5 | |
| SCHEMBL6221780 | 0.80 | ITGB3 (0.76) | ITGB3ITGAVITGB6ITGA2BITGB5 | |
| SCHEMBL6267787 | 0.80 | ITGB3 (0.83) | ITGB3ITGAVITGB6ITGA2BITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1572691-A1 | PYRAZOLE COMPOUNDS AS INTEGRIN RECEPTOR ANTAGONISTS DERIVATIVES | Pharmacia Corporation (US) | 2005-09-14 | — | — | EP | disclosed |
| US-20050004200-A1 | Pyrazole compounds as integrin receptor antagonists derivatives | PHARMACIA CORPORATION | 2005-01-06 | — | — | US | disclosed |
| WO-2004058761-A1 | PYRAZOLE COMPOUNDS AS INTEGRIN RECEPTOR ANTAGONISTS DERIVATIVES | PHARMACIA CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
| WO-2004058761-A1 | PYRAZOLE COMPOUNDS AS INTEGRIN RECEPTOR ANTAGONISTS DERIVATIVES | PHARMACIA CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004200-A1 | Pyrazole compounds as integrin receptor antagonists derivatives | ITGA5, ITGB3, ITGB5 | ITGB3 2/4885ITGAV 4/4885ITGB6 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.